Sulindac Protects Cardiac Myocytes Against Oxidative Damage The initial experiments were designed to determine whether sulindac could protect primary neonatal cardiac myocytes in culture against oxidative damage. The cardiac myocytes were exposed to hypoxia and reoxygenation to promote oxidative damage in the presence or absence of sulindac. Cell viability was then assayed by LDH release. […]
Category: Oncology
The PARP inhibitor olaparib has already shown promise in treating patients with ovarian and breast cancers who have BRCA1 or BRCA2 germline mutations. Now, a study reported in the Journal of Clinical Oncology has found that the drug also shrinks prostate and pancreatic tumors in people who have these mutations. BRCA mutations disable DNA damage […]
Olaparib and Obatoclax In this study, we explored the antitumor activities of the PARP inhibitor AZD2281 (Olaparib) and the pan-Bcl-2 inhibitor GX15-070 (Obatoclax) in six pancreatic cancer cell lines. While both agents were able to cause growth arrest and limited apoptosis, the combination of the two was able to synergistically cause growth arrest and non-apoptotic […]
In this article, we will discuss Olaparib and BRCA Mutations: Synthetic Lethality. So, let’s get started. Synthetic lethality refers to a state where the combination of two genetic alterations leads to cell death, while each alteration alone is survivable. In the context of olaparib and BRCA mutations, the drug exploits this phenomenon by inhibiting PARP […]
In this article, we will discuss Olaparib and BRCA Mutations. So, let’s get started. Olaparib, a pioneering drug in the realm of precision medicine, has emerged as a beacon of hope for individuals with certain types of cancer, particularly those associated with BRCA mutations. The intricate relationship between Olaparib and BRCA mutations unveils a transformative […]